Mesoporous silica nanoparticles in medicine-Recent advances

Advanced Drug Delivery Reviews

Volumn 65, Issue 5, 2013, Pages 689-702

  Mamaeva, Veronika ^a,b   Sahlgren, Cecilia ^a,b   Lindén, Mika ^c  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Biodistribution; Gene delivery; Mesoporous silica; MSN; Nanotoxicology; Targeted drug delivery

Indexed keywords

BIODISTRIBUTIONS; GENE DELIVERY; MESOPOROUS SILICA; MSN; NANOTOXICOLOGY; TARGETED DRUG DELIVERY;

GENE TRANSFER; PHOTODYNAMIC THERAPY;

DRUG DELIVERY;

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; DRUG CARRIER; GAMMA SECRETASE INHIBITOR; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; REACTIVE OXYGEN METABOLITE; SILICON DIOXIDE; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; VERAPAMIL;

BREAST TUMOR; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; EMBRYO DEVELOPMENT; HUMAN; HYDROPHOBICITY; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; UTERUS SARCOMA;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; PHOTOTHERAPY; POROSITY; SILICON DIOXIDE; TISSUE DISTRIBUTION;

EID: 84878347348     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.07.018     Document Type: Review

References (120)

1. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7(9):771-782.
2. Algar W.R., et al. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjug. Chem. 2011, 22(5):825-858.
3. Andersson J., et al. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices. Chem. Mater. 2004, 16(21):4160-4167.
4. Sakamoto J.H., et al. Enabling individualized therapy through nanotechnology. Pharmacol. Res. 2010, 62(2):57-89.
5. Rosenholm J.M., Sahlgren C., Linden M. Cancer-cell targeting and cell-specific delivery by mesoporous silica nanoparticles. J. Mater. Chem. 2010, 20:2707-2713.
6. Rosenholm J.M., Sahlgren C., Linden M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles - opportunities & challenges. Nanoscale 2010, 2(10):1870-1883.
7. Rosenholm J.M., Sahlgren C., Linden M. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment. Curr. Drug Targets 2011, 12(8):1166-1186.
8. Benezra M., et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 2011, 121(7):2768-2780.
9. Lynch I., Salvati A., Dawson K.A. Protein-nanoparticle interactions: what does the cell see?. Nat. Nanotechnol. 2009, 4(9):546-547.
10. Nel A.E., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8(7):543-557.
11. Cedervall T., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(7):2050-2055.
12. Lundqvist M., et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(38):14265-14270.
13. Monopoli M.P., et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 2011, 133(8):2525-2534.
14. Hudson S.P., et al. The biocompatibility of mesoporous silicates. Biomaterials 2008, 29(30):4045-4055.
15. Coti K.K., et al. Mechanised nanoparticles for drug delivery. Nanoscale 2009, 1(1):16-39.
16. Fadeel B., Garcia-Bennett A.E. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv. Drug Deliv. Rev. 2010, 62(3):362-374.
17. Slowing I.I., et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 2008, 60(11):1278-1288.
18. Vivero-Escoto J.L., et al. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 2010, 6(18):1952-1967.
19. Beck J.S., et al. A new family of mesoporous molecular-sieves prepared with liquid-crystal templates. J. Am. Chem. Soc. 1992, 114(27):10834-10843.
20. Kresge C.T., et al. Ordered mesoporous molecular-sieves synthesized by a liquid-crystal template mechanism. Nature 1992, 359(6397):710-712.
21. Yanagisawa T., et al. The preparation of alkyltrimethylammonium-kanemite complexes and their conversion to microporous materials. Bull. Chem. Soc. Jpn. 1990, 63(4):988-992.
22. Grun M., et al. Novel pathways for the preparation of mesoporous MCM-41 materials: control of porosity and morphology. Microporous Mesoporous Mater. 1999, 27(2-3):207-216.
23. Huang X., et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 2011, 5(7):5390-5399.
24. He Q.J., et al. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011, 7(2):271-280.
25. Gao F., et al. Monodispersed mesoporous silica nanoparticles with very large pores for enhanced adsorption and release of DNA. J. Phys. Chem. B 2009, 113(6):1796-1804.
26. Kim M.H., et al. Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery. ACS Nano 2011, 5(5):3568-3576.
27. Zhuravlev L.T. The surface chemistry of amorphous silica. Zhuravlev model. Colloids Surf. A 2000, 173(1-3):1-38.
28. Bernardos A., et al. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with "saccharides". ACS Nano 2010, 4(11):6353-6368.
29. Casasus R., et al. Toward the development of ionically controlled nanoscopic molecular gates. J. Am. Chem. Soc. 2004, 126(28):8612-8613.
30. Gao Q., et al. pH-responsive drug release from polymer-coated mesoporous silica spheres. J. Phys. Chem. C 2009, 113(29):12753-12758.
31. Liu R., et al. pH-responsive nanogated ensemble based on gold-capped mesoporous silica through an acid-labile acetal linker. J. Am. Chem. Soc. 2010, 132(5):1500.
32. Park H.S., et al. A mesoporous silica nanoparticle with charge-convertible pore walls for efficient intracellular protein delivery. Nanotechnology 2010, 21(22).
33. Song S.W., Hidajat K., Kawi S. pH-controllable drug release using hydrogel encapsulated mesoporous silica. Chem. Commun. 2007, 42:4396-4398.
34. Wu J., Sailor M. Chitosan hydrogel-capped porous SiO(2) as a pH responsive nano-valve for triggered release of insulin. Adv. Funct. Mater. 2009, 19(5):733-741.
35. Yang Q., et al. pH-responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery. Chem. Mater. 2005, 17(24):5999-6003.
36. Lai C.Y., et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J. Am. Chem. Soc. 2003, 125(15):4451-4459.
37. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 1999, 284(5415):770-776.
38. Torney F., et al. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat. Nanotechnol. 2007, 2(5):295-300.
39. Aznar E., et al. pH- and photo-switched release of guest molecules from mesoporous silica supports. J. Am. Chem. Soc. 2009, 131(19):6833-6843.
40. Tsai C.P., et al. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J. Mater. Chem. 2009, 19(32):5737-5743.
41. Aznar E., Martinez-Manez R., Sancenon F. Controlled release using mesoporous materials containing gate-like scaffoldings. Expert Opin. Drug Deliv. 2009, 6(6):643-655.
42. Giri S., et al. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew. Chem. Int. Ed. Engl. 2005, 44(32):5038-5044.
43. Fujiwara M., et al. Switching catalytic reaction conducted in pore void of mesoporous material by redox gate control. Chem. Commun. 2006, 44:4635-4637.
44. Gruenhagen J.A., et al. Real-time imaging of tunable adenosine 5-triphosphate release from an MCM-41-type mesoporous silica nanosphere-based delivery system. Appl. Spectrosc. 2005, 59(4):424-431.
45. Liu R., et al. Tunable redox-responsive hybrid nanogated ensembles. J. Am. Chem. Soc. 2008, 130(44):14418.
46. Zhu C.L., et al. An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates. J. Mater. Chem. 2009, 19(41):7765-7770.
47. He Q., et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011, 32(30):7711-7720.
48. Liu J.W., et al. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J. Am. Chem. Soc. 2009, 131(22):7567.
49. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36(1):43-48.
50. Lee J.E., et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J. Am. Chem. Soc. 2010, 132(2):552-557.
51. Hillegass J.M., et al. Increased efficacy of DOXorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int. J. Cancer 2011, 129(1):233-244.
52. Wang T.T., et al. Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy. J. Mater. Chem. 2011, 21(14):5299-5306.
53. Meng H., et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of DOXorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 2011, 5(5):4131-4144.
54. Lu J., et al. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010, 6(16):1794-1805.
55. Lu J., et al. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8(2):212-220.
56. Li L., et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010, 4(11):6874-6882.
57. Cao Y., et al. Cancer research: past present and future. Nat. Rev. Cancer 2011, 11:749-754.
58. Mamaeva V., et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. 2011, 19(8):1538-1546.
59. Wu Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464(7291):1052-1057.
60. Moellering R.E., et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462(7270):182-188.
61. van Es J.H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435(7044):959-963.
62. Yan M., et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463(7282):E6-E7.
63. Xia T.A., et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009, 3(10):3273-3286.
64. Meng H.A., et al. Engineered design of mesoporous silica nanoparticles to deliver DOXorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4(8):4539-4550.
65. Kumar M., et al. Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiency in vitro and in vivo. J. Nanosci. Nanotechnol. 2004, 4(7):876-881.
66. Bharali D.J., et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(32):11539-11544.
67. Li X., Zhang J.X., Gu H.C. Adsorption and desorption behaviors of DNA with magnetic mesoporous silica nanoparticles. Langmuir 2011, 27(10):6099-6106.
68. Li X., et al. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 2011, 32(35):9546-9556.
69. Solberg S.M., Landry C.C. Adsorption of DNA into mesoporous silica. J. Phys. Chem. B 2006, 110(31):15261-15268.
70. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 2008, 65(20):3145-3167.
71. Chen A.M., et al. Co-delivery of DOXorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5(23):2673-2677.
72. Taratula O., et al. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 2011, 19(10):900-914.
73. Huang I.P., et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol. Cancer Ther. 2011, 10(5):761-769.
74. Gary-Bobo M., et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int. J. Pharm. 2012, 423(2):5149-5150.
75. Gary-Bobo M., et al. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. Angew. Chem. Int. Ed. 2011, 50(48):11425-11429.
76. Gary-Bobo M., et al. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy. Int. J. Pharm. 2012, 432(1-2):99-104.
77. Qiao X.F., et al. Triple-functional core-shell structured upconversion luminescent nanoparticles covalently grafted with photosensitizer for luminescent, magnetic resonance imaging and photodynamic therapy in vitro. Nanoscale 2012, 4(15):4611-4623.
78. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater. 2012, 24(28):3747-3756.
79. Sugahara K.N., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328(5981):1031-1035.
80. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188(6):759-768.
81. von Maltzahn G., et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater. 2011, 10(7):545-552.
82. Lu J., et al. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8(2):212-220.
83. Shen S.C., et al. Mesoporous silica nanoparticle-functionalized poly(methyl methacrylate)-based bone cement for effective antibiotics delivery. J. Mater. Sci. Mater. Med. 2011, 22(10):2283-2292.
84. Timchalk C., et al. In vitro and in vivo evaluation of a novel ferrocyanide functionalized nanopourous silica decorporation agent for cesium in rats. Health Phys. 2010, 99(3):420-429.
85. Suwalski A., et al. Accelerated Achilles tendon healing by PDGF gene delivery with mesoporous silica nanoparticles. Biomaterials 2010, 31(19):5237-5245.
86. Armstead A.L., Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int. J. Nanomedicine 2011, 6:3281-3293.
87. Clemens D.L., et al. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob. Agents Chemother. 2012, 56(5):2535-2545.
88. Yu T., et al. Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano 2012, 6(3):2289-2301.
89. Liu T., et al. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials 2011, 32(6):1657-1668.
90. Wu S.H., et al. Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies. ChemBioChem 2008, 9(1):53-57.
91. Lee C.H., et al. Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution. Adv. Funct. Mater. 2009, 19(2):215-222.
92. He Q., et al. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011, 7(2):271-280.
93. Kim J., et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed. 2008, 47(44):8438-8441.
94. Martin K.R. The chemistry of silica and its potential health benefits. J. Nutr. Health Aging 2007, 11(2):94-97.
95. Souris J.S., et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 2010, 31(21):5564-5574.
96. Tanaka T., et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70(9):3687-3696.
97. Vallhov H., et al. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett. 2007, 7(12):3576-3582.
98. Witasp E., et al. Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. Toxicol. Appl. Pharmacol. 2009, 239(3):306-319.
99. Mumin A.M., et al. Dendritic cell internalization of foam-structured fluorescent mesoporous silica nanoparticles. J. Colloid Interface Sci. 2011, 353(1):156-162.
100. Lee S., Yun H.S., Kim S.H. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials 2011, 32(35):9434-9443.
101. Maurer-Jones M.A., Lin Y.S., Haynes C.L. Functional assessment of metal oxide nanoparticle toxicity in immune cells. ACS Nano 2010, 4(6):3363-3373.
102. Ekkapongpisit M., et al. Labeling and exocytosis of secretory compartments in RBL mastocytes by polystyrene and mesoporous silica nanoparticles. Int. J. Nanomedicine 2012, 7:1829-1840.
103. Sharif F., et al. Mesoporous silica nanoparticles as a compound delivery system in zebrafish embryos. Int. J. Nanomedicine 2012, 7:1875-1890.
104. Fubini B., Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic. Biol. Med. 2003, 34(12):1507-1516.
105. Hamilton R.F., Thakur S.A., Holian A. Silica binding and toxicity in alveolar macrophages. Free Radic. Biol. Med. 2008, 44(7):1246-1258.
106. Merchant R.K., Peterson M.W., Hunninghake G.W. Silica directly increases permeability of alveolar epithelial-cells. J. Appl. Physiol. 1990, 68(4):1354-1359.
107. Chen J., et al. Silica increases cytosolic free calcium-ion concentration of alveolar macrophages in vitro. Toxicol. Appl. Pharmacol. 1991, 111(2):211-220.
108. Napierska D., et al. The nanosilica hazard: another variable entity. Part. Fibre Toxicol. 2010, 7.
109. Diaz B., et al. Assessing methods for blood cell cytotoxic responses to inorganic nanoparticles and nanoparticle aggregates. Small 2008, 4(11):2025-2034.
110. Tao Z.M., et al. Accelerated oxidation of epinephrine by silica nanoparticles. Langmuir 2009, 25(17):10183-10188.
111. Heikkilä T., et al. Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells. Eur. J. Pharm. Biopharm. 2010, 74(3):483-494.
112. Ye Y.Y., et al. Nano-SiO(2) induces apoptosis via activation of p53 and Bax mediated by oxidative stress in human hepatic cell line. Toxicol. In Vitro 2010, 24(3):751-758.
113. Nabeshi H., et al. Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. Part. Fibre Toxicol. 2011, 8.
114. Park E.J., Park K. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol. Lett. 2009, 184(1):18-25.
115. Choi J., et al. Silica-based nanoparticle uptake and cellular response by primary microglia. Environ. Heal. Perspect. 2010, 118(5):589-595.
116. Huang X.L., et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 2010, 31(24):6142-6153.
117. Morishige T., et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1 beta production, ROS production and endosomal rupture. Biomaterials 2010, 31(26):6833-6842.
118. Kim J.A., et al. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nanotechnol. 2011, 7(1):62-68.
119. Bhabra G., et al. Nanoparticles can cause DNA damage across a cellular barrier. Nat. Nanotechnol. 2009, 4(12):876-883.
120. Sood A., et al. Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness. Nat. Nanotechnol. 2011, 6(12):824-833.